Open AccessA Phase II Study of Capecitabine, Oxaliplatin, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas
Author(s) -
Uronis Hope E.,
Bendell Johanna C.,
Altomare Ivy,
Blobe Gerard C.,
Hsu S. David,
Morse Michael A.,
Pang Herbert,
Zafar S. Yousuf,
Conkling Paul,
Favaro Justin,
Arrowood Christy C.,
Cushman Stephanie M.,
Meadows Kellen L.,
Brady John C.,
Nixon Andrew B.,
Hurwitz Herbert I.
Publication year - 2013
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2012-0404
Subject(s) - medicine , bevacizumab , capecitabine , oxaliplatin , tolerability , oncology , regimen , clinical endpoint , chemotherapy , gastroenterology , cancer , colorectal cancer , clinical trial , adverse effect
Background. Esophageal and gastric cancers often present at an advanced stage. Systemic chemotherapy is the mainstay of treatment, but survival with current regimens remains poor. We evaluated the safety, tolerability, and efficacy of the combination capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. Methods. Thirty‐seven patients with metastatic or unresectable gastric/gastroesophageal junction tumors were enrolled and treated with capecitabine 850 mg/m 2 BID on days 1–14, and oxaliplatin 130 mg/m 2 with bevacizumab 15 mg/kg on day 1 of a 21‐day cycle. The primary endpoint was progression‐free survival (PFS). Secondary endpoints included response rate (RR) and overall survival (OS). Neuropilin‐1 (NRP1) and ‐2 (NRP2) mRNA expression was evaluated in archived tumor. Results. Thirty‐five patients were evaluable for efficacy. Median PFS was 7.2 months; median OS was 10.8 months. RR was estimated at 51.4%. The regimen was tolerable with expected drug class‐related toxicities. NRP2 mRNA levels significantly correlated with PFS ( p = 0.042) and showed a trend toward significance with OS ( p = 0.051). Nonsignificant trends for NRP1 were noted for higher expression levels and worse outcome. Conclusions. Bevacizumab can be given safely with chemotherapy in patients with metastatic esophagogastric adenocarcinomas. The combination of capecitabine, oxaliplatin, plus bevacizumab has activity comparable to other bevacizumab‐containing regimens in metastatic gastroesophageal cancer.